NCT06660355View on ClinicalTrials.gov

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Chronic Graft-versus-host Disease (cGVHD)

Interventions

DRUG

Ruxolitinib

Ruxolitinib is a Janus kinase inhibitor.

DRUG

Prednisone

Prednisone is a glucocorticoid.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER